Redian新闻
>
4 Biotech With 60% to 100% Upside Potential
avatar
4 Biotech With 60% to 100% Upside Potential# Stock
x*a
1
由最近的康州校园枪击案引发的,因为刚刚身为人母,又和那个地区有某种联系,感触
特别深,请版主手下留情。
下面大部分内容是从另外一个帖子里转过来的。如果觉得美国应该加强枪支管制的话,
请去帖子里的LINK签名。我们不一定要改宪法禁枪,但是请政府加强管制,恢复
FEDERAL ASSAULT WEAPON BAN, 不要让疯子们轻松获得半自动步枪和成百上千发子弹,
在我们孩子的校园外游荡。
1、
https://petitions.whitehouse.gov/petition/immediately-address-issue-gun-
control-through-introduction-legislation-congress/2tgcXzQC
2、
http://www.change.org/petitions/president-barack-obama-support-
-----------------------------
转载网友的:
看看英国的现成例子:
http://en.wikipedia.org/wiki/Gun_politics_in_the_United_Kingdom
英国在1987年和1996发生了两起震惊英伦的有合法拥枪者引发的枪杀案 the
Hungerford massacre of 1987 and the Dunblane school massacre of 1996; each
led to strong public and political demands to restrict firearm use, and
tightening of laws. The result has been among the strictest firearms laws in
the world.
两起事件都引起激烈的公共辩论,并导致英国施行世界上最严格的枪控法案。过了不到
10年就开始见效,从2006年到2012年,连续七年gun-involved homicide incident下降。
In 2006, writing in the British Journal of Criminology, ... found no
measurable effect detectable from the 1997 firearms legislation with ARIMA
statistical analysis, but in subsequent years firearm homicides declined. In
2012 the Home Office reported that, "in 2010/11, firearms were involved in
11,227 recorded offences in England and Wales, the seventh consecutive
annual fall"
现在英国的gun homicides rate世界最低,为0.22/100,000,德国为1.1,而美国是9.0!
The United Kingdom has one of the lowest rates of gun homicides in the world
with 0.22 recorded intentional homicides committed with a firearm per 100,
000 inhabitants compared to the United States' 9.0 and to Germany's 1.1只要
是对的事情就应该去做,哪怕效果显现要二十年,三十年。有一天你会有孩子,你的孩
子会有孩子。
avatar
W*n
2
4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential
By Lee Jackson November 20, 2014 8:55 am EST
In the world of biotech investing, there are some sure-fire ways for stocks
to move. Pipeline announcements, clinical data and regulatory approval all
can move the needle as catalysts for stocks in the industry. A new report
from the biotech team at Stifel has a self-described plethora of catalysts
from companies that are presenting at the firm’s annual health care
conference.
We screened the stocks in the Stifel report for those that were rated Buy at
the firm and had the biggest upside to the analysts’ price objectives.
Array BioPharma Inc. (NASDAQ: ARRY) is a top small cap to buy at Stifel. The
company focuses on the discovery, development and commercialization of
small molecule drugs to treat patients with cancer and inflammatory diseases
, primarily in North America, Europe and the Asia-Pacific. The company’s
MEK inhibitors, binimetinib and selumetinib, are currently advancing in six
Phase 3 trials, and Array’s partners expect the firm’s first regulatory
filing next year with top line results from the other trials available in
2016. In addition, it continues to collect data on the wholly owned
filanesib program in two Phase 2 multiple myeloma trials, including a
randomized combination trial with Kyprolis. With the progress, the company
expects potential commercial revenues within the next two years.
The Stifel price target is $6. The Thomson/First Call consensus is higher at
$7. Shares closed Wednesday at $3.53. Hitting the Stifel target would be a
monster 65% gain.
ALSO READ: 10 Companies That Will Not Be Saved by the Bull Market Alone
Cempra Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. It announced this week that it
has received authorization under its existing contract for the next phase of
its contract with the Biomedical Advanced Research and Development
Authority (BARDA) that will provide funding of $16.0 million for two
clinical studies of solithromycin. The Stifel team views the initial read on
the Solitaire-Oral study as indicating there may be label expansion
possibilities for solithromycin.
The Stifel price target is $22, and the consensus target is $19.50. The
stock closed Wednesday at $13.22. Trading to the Stifel target would be a 63
% gain.
GlycoMimetics Inc. (NASDAQ: GLYC) announced Monday that healthy volunteers
in a Phase 1 clinical study of GMI-1271 tolerated the drug candidate well,
and that the pharmacokinetics for the drug candidate were as predicted based
on preclinical data. The findings represent positive top-line results from
a Phase 1 trial designed to evaluate the safety, tolerability and
pharmacokinetics of GMI-1271, the GlycoMimetics-discovered novel and
proprietary E-selectin antagonist. Based on the data, GlycoMimetics is
planning a Phase 1/2 trial of GMI-1271 as an adjunct to standard
chemotherapy in patients with acute myeloid leukemia. The Stifel team thinks
the drug and clinical work will be very visible at the American Society of
Hematology (ASH) conference to be held next month.
The Stifel price target is $13, and the consensus is higher at $14.67. The
shares closed Wednesday at $7.78. Trading to the Stifel target would be a 72
% gain.
MacroGenics Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical
company focused on discovering and developing innovative monoclonal antibody
-based therapeutics for the treatment of cancer, as well as autoimmune
disorders and infectious diseases. The company generates its pipeline of
product candidates from its proprietary suite of next-generation antibody-
based technology platforms. It announced this week that pre-clinical data on
MGD011, a humanized CD19 x CD3 dual-affinity re-targeting (DART) protein,
will be highlighted in a poster presentation at the ASH.
The Stifel team feels that the company has best-in-class assets in a very
relevant treatment area. The firm puts a $51 price target on the stock, and
the consensus target is $45.83. Shares closed at $23.69. Hitting the Stifel
target would be over a 100% gain for shareholders.
ALSO READ: 7 Analyst Stock Picks Under $10 With Massive Upside Calls
These are extremely aggressive and potentially volatile stocks and trades.
They are only suitable for speculative accounts with a very high risk
tolerance. With that caveat in mind, some big gains could be there for
biotech traders.
By Lee Jackson
avatar
W*g
3
done!
avatar
W*n
4
Man, it also has - 60% to 100% Downside Potential
hahaha
avatar
x*a
5
自己顶顶
谢谢帮顶!
avatar
w*i
6


【在 x*******a 的大作中提到】
: 由最近的康州校园枪击案引发的,因为刚刚身为人母,又和那个地区有某种联系,感触
: 特别深,请版主手下留情。
: 下面大部分内容是从另外一个帖子里转过来的。如果觉得美国应该加强枪支管制的话,
: 请去帖子里的LINK签名。我们不一定要改宪法禁枪,但是请政府加强管制,恢复
: FEDERAL ASSAULT WEAPON BAN, 不要让疯子们轻松获得半自动步枪和成百上千发子弹,
: 在我们孩子的校园外游荡。
: 1、
: https://petitions.whitehouse.gov/petition/immediately-address-issue-gun-
: control-through-introduction-legislation-congress/2tgcXzQC
: 2、

avatar
x*a
7
谢谢!
觉得对的就不要犹豫,十万是十万个一相加。每一个1都很重要!
avatar
s*g
8
签了,但是觉得没用的,奥八没有啥魄力,对军火商没有办法。。。
avatar
x*a
9
多谢!
觉得对的事情就去做。一万 = 一万个一相加。
千里之行始于足下。
我对奥巴有信心。多少人没做成的医疗改革从他这里开始了,尽管有很多不尽人意的地
方,总是成功的开始。至少现在保险公司不能据PREXISTING CONDITION了,至少全民要
有医保了。。。。

【在 s**********g 的大作中提到】
: 签了,但是觉得没用的,奥八没有啥魄力,对军火商没有办法。。。
avatar
s*g
10
希望能成。 但是奥八一直都无法给富豪加税啊,医疗改革会导致赤字越来越大。。。
长远看来不知道是喜是忧

【在 x*******a 的大作中提到】
: 多谢!
: 觉得对的事情就去做。一万 = 一万个一相加。
: 千里之行始于足下。
: 我对奥巴有信心。多少人没做成的医疗改革从他这里开始了,尽管有很多不尽人意的地
: 方,总是成功的开始。至少现在保险公司不能据PREXISTING CONDITION了,至少全民要
: 有医保了。。。。

avatar
x*a
11
赤字始于小布什。最烧钱的不是医改是打仗。
只要不打仗,钱会回来的。

【在 s**********g 的大作中提到】
: 希望能成。 但是奥八一直都无法给富豪加税啊,医疗改革会导致赤字越来越大。。。
: 长远看来不知道是喜是忧

avatar
x*a
12
https://petitions.whitehouse.gov/petition/immediately-address-issue-gun-
control-through-introduction-legislation-congress/2tgcXzQC
短短两天,已经13万六千人签名了,希望明天上班以后会有更多的人。
希望同意签字的人也能把这个LINK转给每一个你知道的同意加强控枪和禁枪的人。
与其花力气去试图说服一些无法说服的人,不如尽力去团结和自己一样的人,让我们的
声音被有力量做改变的人听到。
一个人的声音和力量都很小,但是十万也只是十万个一相加,也要靠十万个一来相加。
如果觉得你的想法是对的,就去做吧,为了孩子。
avatar
W*g
13
我不富,但也不支持总盘算着给富豪加税,让他那群懒弟兄自食其力就阿弥陀佛啦

【在 s**********g 的大作中提到】
: 希望能成。 但是奥八一直都无法给富豪加税啊,医疗改革会导致赤字越来越大。。。
: 长远看来不知道是喜是忧

avatar
a*a
14
Support
avatar
s*g
15
现在没加上税,还是很多人专门靠吃福利为生啊。。。。。。。

【在 W*******g 的大作中提到】
: 我不富,但也不支持总盘算着给富豪加税,让他那群懒弟兄自食其力就阿弥陀佛啦
avatar
h*2
16
Done
avatar
x*a
17
谢谢!
真没什么好争的。人心所向,数据证明。
支持控枪的,159344
https://petitions.whitehouse.gov/petition/immediately-address-issue-gun-
control-through-introduction-legislation-congress/2tgcXzQC
还有其他好几个,都是5位数了。
要求别控枪的, 3940
https://petitions.whitehouse.gov/petition/dissolve-any-petitions-assault-
weapons-ban-unconstitutional-under-amendment-ii-constitution/KNQrsC8V
我今天拉了几个老美。都是人家明确表示需要控枪的,我跟上说,赶快去SIGN。大多数
支持控枪的人其实还不知道这个LINK。

【在 h*******2 的大作中提到】
: Done
相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。